1 Min Read
Jan 25 (Reuters) - Soligenix Inc:
* SOLIGENIX - DRIVING TOWARDS KEY INFLECTION POINTS WITH TWO PIVOTAL PHASE 3 CLINICAL TRIALS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.